A recent clinical trial found that combining the oral medication baricitinib with narrowband UV-B light therapy significantly improves outcomes for adults with severe and active nonsegmental vitiligo.

Within the baricitinib group, patients experienced a mean Vitiligo Area Scoring Index score change of 44.8% from baseline to week 36. In contrast, the placebo group saw a 9.2% change. The Janus ...

A recent breakthrough by researchers from Shinshu University, Japan, is changing this landscape. The team has successfully achieved the first total synthesis of inaoside A, a natural compound found in ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- For adults with severe, active, nonsegmental vitiligo, baricitinib combined with narrowband ultraviolet light B (UV-B) is efficacious compared with placebo ...

"Although the α-D-ribofuranoside structure is frequently found in natural products, there have been fewer reports of the synthesis of α-D-ribofuranosides than of the β-anomers. Thus, the ...

Baricitinib, a Janus kinase (JAK) inhibitor, combined with narrowband ultraviolet B (UVB) phototherapy, reduced disease activity and improved repigmentation and quality of life in adults with ...

Baricitinib can effectively treat polymyalgia rheumatica (PMR) without the use of oral glucocorticoids, according to results from a small, randomized, double-blind, placebo-controlled study.